The FDA issued an emergency use authorization for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant.
Read more: Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant